端粒酶联合CA125检测在上皮性卵巢癌诊断中的价值

Significance of Telomerase Expression Associated with Serum CA125 Levels in Diagnosis of Ovarian Carcinoma

目的探讨端粒酶定量检测联合血清CA125测定在上皮性卵巢癌诊断中的临床意义。方法采用RTQ-PCR法(实时定量端粒重复扩增PCR法)定量检测卵巢上皮性癌组织20例、良性卵巢肿瘤组织5例、12例正常卵巢组织中的端粒酶活性,同时以放免法检测其血清CA125值。结果上皮性卵巢癌Ⅰ～Ⅱ期患者的端粒酶值(197.10±28.20)明显高于Ⅲ～Ⅳ期患者(347.14±60.10)(P<0.05);而与肿瘤组织学分类无关(P>0.05);患者血清CA125水平则与病理类型有关,浆液性囊腺癌组高于黏液性囊腺癌组(P<0.05),而其与临床分期无相关性(P>0.05)。结论端粒酶定量检测联合血清CA125测定有助于卵巢癌的诊断及预后监测。

Objective To evaluate the clinic signicicance of the combined quantitative detection of hTR and specific serum marker of ovarian cancer CA125. Methods The expression of telomerase activity was measured with RTQ-PCR and frezon ovarian tissue specimens in 20 cases of Ovarian carcinoma, 5 cases of ovarian benign tumor and 12 cases of normal ovary of nontumor gynecology. The serum CA125 levels was measured by radioimmunoassay in 20 cases of ovarian carcinoma before operation. Results The result of telomerase was significantly different between clinical stage Ⅰ-Ⅱ （197. 10 ± 28.20） and clinical stage Ⅲ - Ⅳ （347. 14 ±60. 10） （P 〈 0. 05）, but there was no correlation with type of ovarian epithelial tumors（ P 〉 0.05） . The level of serum CA125 was related to pathology. The level of CA125 in patients with serous cystadenocarcinoma was higher than that in the patient with mucinous cystadenocarcinoma（ P 〈 0.05）, but there was no correlation with clinical stage（ P 〉 0.05） . Conclusion The combined quantitative detection of hTR and serum CA125 are helpful to the diagnosis of ovarian cancer.